Skip to content

Active Monitoring versus an Abduction Device for treatment of Infants with Centered Dysplastic Hips, a Comprehensive Cohort Study (TReatment with Active Monitoring (TRAM)-Trial)

Active Monitoring versus an Abduction Device for treatment of Infants with Centered Dysplastic Hips, a Comprehensive Cohort Study (TReatment with Active Monitoring (TRAM)-Trial) - The TRAM-Trial: Treatment with Active Monitoring

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56369
Enrollment
800
Registered
2022-03-04
Start date
2022-05-25
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abnormal hip development hip dysplasia

Interventions

use of the Pavlik harness (abduction treatment)

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: - patients with Graf 2a- or 2b or 2c DDH -10-20 weeks old -good command of the dutch language of the parents -parental informed consent

Exclusion criteria

Exclusion criteria: -hip instability -(suspicion of) syndromal disease -prematurity (defined as a gestational age

Design outcomes

Primary

MeasureTime frame
active monitoring of infants with stable centered DDH (Graf type IIa-/IIb/IIc) does not result in a lower proportion of infants with normal hips (success: acetabular index lower than 25 degrees on radiograph) at the age of 12 months compared to abduction treatment (a non-inferiority study).

Secondary

MeasureTime frame
- What is the difference in success rate between both study groups at the age of 24 months? - Do fewer complications occur when infants are treated with active monitoring compared to treatment with a dynamic abduction device? - What is the difference in time to Graf I? - Which factors are associated with the outcome at 12 and 24 months? - Are parents compliant to the abduction device? - Is treatment with active monitoring cost effective to treatment with a dynamic abduction device? - What is the quality of life of the infants and of the parents? - Is parent-satisfaction different between both treatment options?

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)